Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for NASH with fibrosis stage 2 or 3
NL-OMON60696Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Semaglutide with Placebo (2 arms). Primary endpoints: Resolution of steatohepatitis and no worsening of liver fibrosis, Improvement in liver fibrosis and no worsening of steatohepatitis and 1 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON60696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60696.